Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer

2016 ◽  
pp. 1 ◽  
Author(s):  
Gabriele Siesto ◽  
Raffaele Cavina ◽  
Fabrizio Romano ◽  
Domenico Vitobello
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Debulking Surgery ◽  
Primary Debulking Surgery ◽  
Advanced Epithelial Ovarian Cancer

Randomized Trial of Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Advanced Epithelial Ovarian Cancer (SCORPION-NCT01461850)

2021 ◽  
Vol 76 (2) ◽  
pp. 90-91
Author(s):  
Anna Fagotti ◽  
Maria Gabriella Ferrandina ◽  
Giuseppe Vizzielli ◽  
Tina Pasciuto ◽  
Francesco Fanfani ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Randomized Trial ◽  
Debulking Surgery ◽  
Primary Debulking Surgery ◽  
Advanced Epithelial Ovarian Cancer

Comparative analysis of neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16596-16596
Author(s):  
S. J. Sirop ◽  
S. Saha ◽  
D. Iddings ◽  
M. Ghanem ◽  
N. Dutt ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Comparative Analysis ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Debulking Surgery ◽  
Primary Debulking Surgery ◽  
Advanced Epithelial Ovarian Cancer

scholarly journals Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome

PLoS ONE ◽  
2017 ◽  
Vol 12 (10) ◽  
pp. e0186725 ◽  
Author(s):  
Lijuan Yang ◽  
Bo Zhang ◽  
Guangyang Xing ◽  
Jingran Du ◽  
Bin Yang ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Meta Analysis ◽  
Debulking Surgery ◽  
Primary Debulking Surgery ◽  
Operative Outcome ◽  
Advanced Epithelial Ovarian Cancer

Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 5516-5516 ◽  
Author(s):  
Anna Fagotti ◽  
Giuseppe Vizzielli ◽  
Gabriella Ferrandina ◽  
Francesco Fanfani ◽  
Valerio Gallotta ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Epithelial Ovarian Cancer ◽  
Randomized Trial ◽  
Debulking Surgery ◽  
Survival Analyses ◽  
Primary Debulking Surgery ◽  
Tumor Load ◽  
Advanced Epithelial Ovarian Cancer

Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study

2016 ◽  
Vol 27 (1) ◽  
pp. 28-36 ◽  
Author(s):  
Angiolo Gadducci ◽  
Stefania Cosio ◽  
Valentina Zizioli ◽  
Sara Notaro ◽  
Roberta Tana ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Retrospective Study ◽  
Neoadjuvant Chemotherapy ◽  
Clinical Outcome ◽  
Epithelial Ovarian Cancer ◽  
Recurrence Rate ◽  
Complete Response ◽  
Debulking Surgery ◽  
Primary Debulking Surgery ◽  
Interval Debulking Surgery

ObjectiveThe objective of this retrospective study was to assess the clinical outcome of patients with advanced epithelial ovarian cancer in complete response after primary debulking surgery (PDS) or neoadjuvant chemotherapy followed by interval debulking surgery (IDS]).MethodsThe authors reviewed the hospital records of 384 patients who underwent PDS (n = 322) or IDS (n = 62) and who were in complete response after primary treatment.ResultsOptimal (residual disease [RD] < 1 cm) and complete (no gross RD) cytoreduction rates were higher after IDS than after PDS (71.0% vs 55.9%;P= 0.001 and 51.6% vs 35.7%, respectively;P= 0.02). Tumor recurred in 73.0% of the 322 complete responders after PDS versus 87.1% of the 62 complete responders after IDS (P= 0.01). The IDS group showed a higher recurrence rate within 6 months (11.3% vs 3.1%:P= 0.01) and a trend to higher recurrence rate between 6 and 12 months (30.6% vs 19.9%). Tumor recurred in 57.4% of the 115 completely cytoreduced patients after PDS versus 87.5% of the 32 completely cytoreduced patients after IDS (P= 0.001). The IDS group showed a trend to higher recurrence rate within 6 months (6.2% vs 1.7%) and a higher recurrence rate between 6 and 12 months (37.5% vs 15.6%;P= 0.01). Two-year, 5-year, and 7-year progression-free survival were 65.8%, 40.8%, and 39.3% for completely cytoreduced patients after PDS versus 43.8%, 12.5%, and 12.5% for completely cytoreduced patients after IDS (P= 0.001); and 2-year, 5-year, and 7-year overall survival were 96.4%, 69.3%, and 50.4% for the former versus 87.1%, 41.8%, and 32.6% for the latter (P= 0.001).ConclusionsThe clinical outcome of completely cytoreduced patients was significantly better for PDS group than for IDS group, and therefore, the achievement of no gross RD after surgery seemed to have a different prognostic relevance for the 2 groups.

Sign in / Sign up

Export Citation Format

Share Document